- Eli Lilly And Co LLY posted data from the SURPASS-3 CGM sub-study of tirzepatide in a subpopulation of 243 participants who wore continuous glucose monitoring (CGM) for 7 to 10 days at baseline.
- Related Link: Eli Lilly's Tirzepatide Tops Novo's Semaglutide In Late-Stage Diabetes Study.
- All three tirzepatide doses led to more time in tight target range (71-140 mg/dL), improved glycemic variability, and numerically less time in hypoglycemia than titrated insulin degludec in adults with type 2 diabetes.
- Specifically, at 52 weeks, participants taking tirzepatide spent 72.6% of the 24 hours in tight target range (71-140 mg/dL) for pooled 10 mg and 15 mg arms, an average of approximately six more hours than those taking insulin degludec (48.0%).
- Lilly also shared data MRI sub-study showing that tirzepatide led to greater improvements in liver fat content (LFC) and abdominal adipose tissue than titrated insulin degludec in adults with type 2 diabetes.
- Participants taking tirzepatide at 52 weeks showed a greater absolute reduction from baseline in LFC for pooled 10 mg and 15 mg arms (-8.09% from 15.67% at baseline) than insulin degludec (-3.38% from 16.58% at baseline), the primary endpoint.
- Also, a greater relative reduction from baseline in LFC (29.78%-47.11% across the three doses) compared to 11.17% for insulin degludec.
- The data were presented at the 57th European Association for the Study of Diabetes Annual Meeting.
- Also Read: Eli Lilly's Tirzepatide Non-Inferior To Titrated Insulin Glargine In Type 2 Diabetes Patients.
- Price Action: LLY stock traded 0.16% higher at $230.72 premarket on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
